Spectrum Pharmaceuticals, Inc.
Combination therapy using belinostat and pralatrexate to treat lymphoma
Last updated:
Abstract:
The present invention relates to compositions and methods for treating lymphoma in a subject in need thereof, said methods comprising administering to the patient in need thereof a therapeutically effective amount of a combination of belinostat and pralatrexate, wherein said therapeutically effective amount results in a synergistic antiproliferative effect on cancer cell growth.
Status:
Grant
Type:
Utility
Filling date:
14 Jun 2016
Issue date:
13 Sep 2022